Piper Sandler Maintains Overweight on Abbott Laboratories, Raises Price Target to $133
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler has maintained an Overweight rating on Abbott Laboratories and raised its price target from $131 to $133.
October 17, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has maintained an Overweight rating on Abbott Laboratories and increased the price target from $131 to $133, indicating a positive outlook.
The maintenance of an Overweight rating and the increase in the price target by Piper Sandler suggests a positive sentiment towards Abbott Laboratories. This is likely to have a favorable impact on the stock price in the short term as it reflects confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100